Global Guide of Coming Off-patent Agrochemical Active Ingredients[Edition8]

Keyword:
Publish time:8/26/2021 12:00:00 AM      Source: CCM
Information collection and data processing:  CCM     For more information, please contact us
Global Guide of Coming Off-patent Agrochemical Active Ingredients, finished in August 2021, is CCM's eighth edition report on coming off-patent agrochemicals in the world. This report contains profiles of 17 active ingredients (7 herbicides, 4 insecticides, 6 fungicides) whose patents will expire in 2021–2028.

Among the 17 active ingredients, 10 of which had been registered in at least ten countries among the 17 target ones as of August 2021.

Among the 17 target countries, there were 2 countries where at least 15 active ingredients had been registered as of August 2021.

In this report, CCM will introduce global guide of coming off-patent agrochemical active ingredients from the following aspects:

√ Basic information
√ Chemical structure
√ History
√ Synthesis route
√ Application
√ Physical & safety data
√ Patent information

√ Registration information



Main contents:

No. Content


Executive summary

Methodology and scope
1 Profiles of coming off-patent herbicides
1.1 Aminopyralid
1.2 Pyrasulfotole
1.3 Pyroxasulfone
1.4 Pyroxsulam
1.5 Saflufenacil
1.6 Indaziflam
1.7 Cyprosulfamide
2 Profiles of coming off-patent insecticides
2.1 Chlorantraniliprole
2.2 Cyantraniliprole
2.3 Cyclaniliprole
2.4 Spirotetramat
3 Profiles of coming off-patent fungicides
3.1 Mandipropamid
3.2 Penflufen
3.3 Bixafen
3.4 Fluopyram
3.5 Isopyrazam
3.6 Sedaxane



List of tables:

Table No. Table Title
Table 1.1-1 Patent information of aminopyralid in some countries/regions, as of July 2021
Table 1.1-2 Registration information of aminopyralid in Argentina, as of July 2021
Table 1.1-3 Registration information of aminopyralid in Australia, as of July 2021
Table 1.1-4 Registration information of aminopyralid in Belgium, as of July 2021
Table 1.1-5 Registration information of aminopyralid in Brazil, as of July 2021
Table 1.1-6 Registration information of aminopyralid in Canada, as of July 2021
Table 1.1-7 Registration information of aminopyralid in China, as of July 2021
Table 1.1-8 Registration information of aminopyralid in Denmark, as of July 2021
Table 1.1-9 Registration information of aminopyralid in Finland, as of July 2021
Table 1.1-10 Registration information of aminopyralid in France, as of July 2021
Table 1.1-11 Registration information of aminopyralid in Greece, as of July 2021
Table 1.1-12 Registration information of aminopyralid in the Netherlands, as of July 2021
Table 1.1-13 Registration information of aminopyralid in South Africa, as of April 2019
Table 1.1-14 Registration information of aminopyralid in Switzerland, as of July 2021
Table 1.1-15 Registration information of aminopyralid in the UK, as of July 2021
Table 1.1-16 Registration information of aminopyralid in Uruguay, as of July 2021
Table 1.1-17 Registration information of aminopyralid in the US, as of July 2021
Table 1.2-1 Patent information of pyrasulfotole in some countries/regions, as of July 2021
Table 1.2-2 Registration information of pyrasulfotole in Australia, as of July 2021
Table 1.2-3 Registration information of pyrasulfotole in Canada, as of July 2021
Table 1.2-4 Registration information of pyrasulfotole in South Africa, as of April 2019
Table 1.2-5 Registration information of pyrasulfotole in the US, as of July 2021
Table 1.3-1 Patent information of pyroxasulfone in some countries/regions, as of July 2021
Table 1.3-2 Registration information of pyroxasulfone in Argentina, as of July 2021
Table 1.3-3 Registration information of pyroxasulfone in Australia, as of July 2021
Table 1.3-4 Registration information of pyroxasulfone in Brazil, as of July 2021
Table 1.3-5 Registration information of pyroxasulfone in Canada, as of July 2021
Table 1.3-6 Registration information of pyroxasulfone in China, as of July 2021
Table 1.3-7 Registration information of pyroxasulfone in South Africa, as of April 2019
Table 1.4-1 Patent information of pyroxsulam in some countries/regions, as of July 2021
Table 1.4-2 Registration information of pyroxsulam in Australia, as of July 2021
Table 1.4-3 Registration information of pyroxsulam in Belgium, as of July 2021
Table 1.4-4 Registration information of pyroxsulam in Brazil, as of July 2021
Table 1.4-5 Registration information of pyroxsulam in Canada, as of July 2021
Table 1.4-6 Registration information of pyroxsulam in China, as of July 2021
Table 1.4-7 Registration information of pyroxsulam in Denmark, as of July 2021
Table 1.4-8 Registration information of pyroxsulam in France, as of July 2021
Table 1.4-9 Registration information of pyroxsulam in Greece, as of July 2021
Table 1.4-10 Registration information of pyroxsulam in the Netherlands, as of July 2021
Table 1.4-11 Registration information of pyroxsulam in South Africa, as of April 2019
Table 1.4-12 Registration information of pyroxsulam in Switzerland, as of July 2021
Table 1.4-13 Registration information of pyroxsulam in the UK, as of July 2021
Table 1.4-14 Registration information of pyroxsulam in the US, as of July 2021
Table 1.5-1 Patent information of saflufenacil in some countries/regions, as of July 2021
Table 1.5-2 Registration information of saflufenacil in Argentina, as of July 2021
Table 1.5-3 Registration information of saflufenacil in Australia, as of July 2021
Table 1.5-4 Registration information of saflufenacil in Brazil, as of July 2021
Table 1.5-5 Registration information of saflufenacil in Canada, as of July 2021
Table 1.5-6 Registration information of saflufenacil in Chile, as of July 2021
Table 1.5-7 Registration information of saflufenacil in China, as of July 2021
Table 1.5-8 Registration information of saflufenacil in South Africa, as of April 2019
Table 1.5-9 Registration information of saflufenacil in Uruguay, as of July 2021
Table 1.6-1 Patent information of indaziflam in some countries/regions, as of July 2021
Table 1.6-2 Registration information of indaziflam in Argentina, as of July 2021
Table 1.6-3 Registration information of indaziflam in Australia, as of July 2021
Table 1.6-4 Registration information of indaziflam in Brazil, as of July 2021
Table 1.6-5 Registration information of indaziflam in Canada, as of July 2021
Table 1.6-6 Registration information of indaziflam in Chile, as of July 2021
Table 1.6-7 Registration information of indaziflam in South Africa, as of April 2019
Table 1.6-8 Registration information of indaziflam in Uruguay, as of July 2021
Table 1.6-9 Registration information of indaziflam in the US, as of July 2021
Table 1.7-1 Patent information of cyprosulfamide in some countries/regions, as of July 2021
Table 1.7-2 Registration information of cyprosulfamide in Argentina, as of July 2021
Table 1.7-3 Registration information of cyprosulfamide in Belgium, as of July 2021
Table 1.7-4 Registration information of cyprosulfamide in Canada, as of July 2021
Table 1.7-5 Registration information of Cyprosulfamide in Chile, as of July 2021
Table 1.7-6 Registration information of cyprosulfamide in France, as of July 2021
Table 1.7-7 Registration information of cyprosulfamide in Greece, as of July 2021
Table 1.7-8 Registration information of cyprosulfamide in the Netherlands, as of July 2021
Table 2.1-1 Patent information of chlorantraniliprole in some countries/regions, as of July 2021
Table 2.1-2 Registration information of chlorantraniliprole in Australia, as of July 2021
Table 2.1-3 Registration information of chlorantraniliprole in Canada, as of July 2021
Table 2.1-4 Registration information of chlorantraniliprole in China, as of July 2021
Table 2.1-5 Registration information of Chlorantraniliprole in Finland, as of July 2021
Table 2.1-6 Registration information of chlorantraniliprole in France, as of July 2021
Table 2.1-7 Registration information of chlorantraniliprole in Greece, as of July 2021
Table 2.1-8 Registration information of chlorantraniliprole in the Netherlands, as of July 2021
Table 2.1-9 Registration information of chlorantraniliprole in South Africa, as of April 2019
Table 2.1-10 Registration information of chlorantraniliprole in Switzerland, as of July 2021
Table 2.1-11 Registration information of chlorantraniliprole in the UK, as of July 2021
Table 2.1-12 Registration information of chlorantraniliprole in Uruguay, as of July 2021
Table 2.1-13 Registration information of chlorantraniliprole in the US, as of July 2021
Table 2.2-1 Patent information of cyantraniliprole in some countries/regions, as of July 2021
Table 2.2-2 Registration information of cyantraniliprole in Argentina, as of July 2021
Table 2.2-3 Registration information of cyantraniliprole in Australia, as of July 2021
Table 2.2-4 Registration information of cyantraniliprole in Belgium, as of July 2021
Table 2.2-5 Registration information of cyantraniliprole in Canada, as of July 2021
Table 2.2-6 Registration information of cyantraniliprole in China, as of July 2021
Table 2.2-7 Registration information of cyantraniliprole in Finland, as of July 2021
Table 2.2-8 Registration information of cyantraniliprole in France, as of July 2021
Table 2.2-9 Registration information of cyantraniliprole in Greece, as of July 2021
Table 2.2-10 Registration information of cyantraniliprole in the Netherlands, as of July 2021
Table 2.2-11 Registration information of cyantraniliprole in South Africa, as of April 2019
Table 2.2-12 Registration information of cyantraniliprole in the UK, as of July 2021
Table 2.2-13 Registration information of cyantraniliprole in Uruguay, as of July 2021
Table 2.2-14 Registration information of cyantraniliprole in the US, as of July 2021
Table 2.3-1 Patent information of cyclaniliprole in some countries/regions, as of July 2021
Table 2.3-2 Registration information of cyclaniliprolen in Australia, as of July 2021
Table 2.3-3 Registration information of cyclaniliprole in Canada, as of July 2021
Table 2.3-4 Registration information of cyclaniliprole in the US, as of July 2021
Table 2.4-1 Patent information of spirotetramat in some countries/regions, as of July 2021
Table 2.4-2 Registration information of spirotetramat in Australia, as of July 2021
Table 2.4-3 Registration information of spirotetramat in Canada, as of July 2021
Table 2.4-4 Registration information of Spirotetramat in Chile, as of July 2021
Table 2.4-5 Registration information of spirotetramat in China, as of July 2021
Table 2.4-6 Registration information of spirotetramat in Denmark, as of July 2021
Table 2.4-7 Registration information of spirotetramat in France, as of July 2021
Table 2.4-8 Registration information of spirotetramat in Greece, as of July 2021
Table 2.4-9 Registration information of spirotetramat in the Netherlands, as of July 2021
Table 2.4-10 Registration information of spirotetramat in the Switzerland, as of July 2021
Table 2.4-11 Registration information of spirotetramat in the UK, as of July 2021
Table 2.4-12 Registration information of spirotetramat in Uruguay, as of July 2021
Table 2.4-13 Registration information of spirotetramat in the US, as of July 2021
Table 3.1-1 Patent information of mandipropamid in some countries/regions, as of July 2021
Table 3.1-2 Registration information of mandipropamid in Argentina, as of July 2021
Table 3.1-3 Registration information of mandipropamid in Australia, as of July 2021
Table 3.1-4 Registration information of mandipropamid in Belgium, as of July 2021
Table 3.1-5 Registration information of mandipropamid in Brazil, as of July 2021
Table 3.1-6 Registration information of mandipropamid in Canada, as of July 2021
Table 3.1-7 Registration information of mandipropamid in Chile, as of July 2021
Table 3.1-8 Registration information of mandipropamid in China, as of July 2021
Table 3.1-9 Registration information of mandipropamid in Denmark, as of July 2021
Table 3.1-10 Registration information of mandipropamid in Finland, as of July 2021
Table 3.1-11 Registration information of mandipropamid in France, as of July 2021
Table 3.1-12 Registration information of mandipropamid in Greece, as of July 2021
Table 3.1-13 Registration information of mandipropamid in the Netherlands, as of July 2021
Table 3.1-14 Registration information of mandipropamid in South Africa, as of April 2019
Table 3.1-15 Registration information of mandipropamid in Switzerland, as of July 2021
Table 3.1-16 Registration information of mandipropamid in the UK, as of July 2021
Table 3.1-17 Registration information of mandipropamid in the US, as of July 2021
Table 3.2-1 Patent information of penflufen in some countries/regions, as of July 2021
Table 3.2-2 Registration information of penflufen in Australia, as of July 2021
Table 3.2-3 Registration information of penflufen in Belgium, as of July 2021
Table 3.2-4 Registration information of penflufen in Canada, as of July 2021
Table 3.2-5 Registration information of penflufen in Chile, as of July 2021
Table 3.2-6 Registration information of penflufen in China, as of July 2021
Table 3.2-7 Registration information of penflufen in Finland, as of July 2021
Table 3.2-8 Registration information of penflufen in the Netherlands, as of July 2021
Table 3.2-9 Registration information of penflufen in the UK, as of July 2021
Table 3.2-10 Registration information of penflufen in the US, as of July 2021
Table 3.3-1 Patent information of bixafen in some countries/regions, as of July 2021
Table 3.3-2 Registration information of bixafen in Argentina, as of July 2021
Table 3.3-3 Registration information of bixafen in Australia, as of July 2021
Table 3.3-4 Registration information of bixafen in Belgium, as of July 2021
Table 3.3-5 Registration information of Bixafen in Canada, as of July 2021
Table 3.3-6 Registration information of bixafen in Chile, as of July 2021
Table 3.3-7 Registration information of bixafen in Denmark, as of July 2021
Table 3.3-8 Registration information of bixafen in Finland, as of July 2021
Table 3.3-9 Registration information of bixafen in France, as of July 2021
Table 3.3-10 Registration information of bixafen in the Netherlands, as of July 2021
Table 3.3-11 Registration information of bixafen in South Africa, as of April 2019
Table 3.3-12 Registration information of bixafen in Switzerland, as of July 2021
Table 3.3-13 Registration information of bixafen in the UK, as of July 2021
Table 3.3-14 Registration information of bixafen in Uruguay, as of July 2021
Table 3.3-15 Registration information of bixafen in the US, as of July 2021
Table 3.4-1 Patent information of fluopyram in some countries/regions, as of July 2021
Table 3.4-2 Registration information of fluopyram in Australia, as of July 2021
Table 3.4-3 Registration information of fluopyram in Belgium, as of July 2021
Table 3.4-4 Registration information of fluopyram in Brazil, as of July 2021
Table 3.4-5 Registration information of fluopyram in Canada, as of July 2021
Table 3.4-6 Registration information of fluopyram in China, as of July 2021
Table 3.4-7 Registration information of fluopyram in Denmark, as of July 2021
Table 3.4-8 Registration information of fluopyram in Finland, as of July 2021
Table 3.4-9 Registration information of fluopyram in France, as of July 2021
Table 3.4-10 Registration information of fluopyram in Greece, as of July 2021
Table 3.4-11 Registration information of fluopyram in the Netherlands, as of July 2021
Table 3.4-12 Registration information of fluopyram in South Africa, as of April 2019
Table 3.4-13 Registration information of fluopyram in Switzerland, as of July 2021
Table 3.4-14 Registration information of fluopyram in the UK, as of July 2021
Table 3.4-15 Registration information of fluopyram in the US, as of July 2021
Table 3.5-1 Patent information of isopyrazam in some countries/regions, as of July 2021
Table 3.5-2 Registration information of isopyrazam in Argentina, as of July 2021
Table 3.5-3 Registration information of isopyrazam in Australia, as of July 2021
Table 3.5-4 Registration information of isopyrazam in Belgium, as of July 2021
Table 3.5-5 Registration information of isopyrazam in China, as of July 2021
Table 3.5-6 Registration information of isopyrazam in Finland, as of July 2021
Table 3.5-7 Registration information of isopyrazam in France, as of July 2021
Table 3.5-8 Registration information of isopyrazam in Greece, as of July 2021
Table 3.5-9 Registration information of isopyrazam in the Netherlands, as of July 2021
Table 3.5-10 Registration information of isopyrazam in the UK, as of July 2021
Table 3.5-11 Registration information of isopyrazam in Uruguay, as of July 2021
Table 3.6-1 Patent information of sedaxane in some countries/regions, as of July 2021
Table 3.6-2 Registration information of sedaxane in Argentina, as of July 2021
Table 3.6-3 Registration information of sedaxane in Australia, as of July 2021
Table 3.6-4 Registration information of sedaxane in Canada, as of July 2021
Table 3.6-5 Registration information of sedaxane in Chile, as of July 2021
Table 3.6-6 Registration information of sedaxane in China, as of July 2021
Table 3.6-7 Registration information of sedaxane in Denmark, as of July 2021
Table 3.6-8 Registration information of sedaxane in Finland, as of July 2021
Table 3.6-9 Registration information of sedaxane in France, as of July 2021
Table 3.6-10 Registration information of sedaxane in Greece, as of July 2021
Table 3.6-11 Registration information of sedaxane in the UK, as of July 2021
Table 3.6-12 Registration information of sedaxane in Uruguay, as of July 2021
Table 3.6-13 Registration information of sedaxane in the US, as of July 2021


List of figures:

Figure No. Figure Title
Figure 1.1-1 Chemical structure of aminopyralid
Figure 1.2-1 Chemical structure of pyrasulfotole
Figure 1.3-1 Chemical structure of Pyroxasulfone
Figure 1.4-1 Chemical structure of pyroxsulam
Figure 1.5-1 Chemical structure of saflufenacil
Figure 1.7-1 Chemical structure of cyprosulfamide
Figure 2.1-1 Chemical structure of chlorantraniliprole
Figure 2.2-1 Chemical structure of cyantraniliprole
Figure 2.3-1 Chemical structure of cyclaniliprole
Figure 2.3-2 Route for synthesizing cyclaniliprole
Figure 2.4-1 Chemical structure of spirotetramat
Figure 2.4-2 Route for synthesizing spirotetramat
Figure 3.1-1 Chemical structure of mandipropamid
Figure 3.2-1 Chemical structure of penflufen
Figure 3.3-1 Chemical structure of bixafen
Figure 3.4-1 Chemical structure of fluopyram
Figure 3.5-1 Chemical structure of isopyrazam
Figure 3.6-1 Chemical structure of sedaxane


Get the sample report of <Global Guide of Coming Off-patent Agrochemical Active Ingredients[Edition8]> now.


About CCM:

CCM is the leading market intelligence provider for China’s agriculture, chemicals, food & feed and life science markets. Founded in 2001, CCM offers a range of data and content solutions, from price and trade data to industry newsletters and customized market research reports. CCM is a brand of Kcomber Inc.

 
For more information about CCM, please visit www.cnchemicals.com or get in touch with us directly by emailing emarket1@cnchemicals.com or calling +86-20-37616606.